- Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors
- Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024
- Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024
CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation,today provides a corporate update for the third quarter ending September 30, 2023 and to date:
Highlights:
Login or create a forever free account to read this news
Sign up/Log in